Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer
Authors
Keywords
-
Journal
Expert Review of Anticancer Therapy
Volume 14, Issue 5, Pages 511-521
Publisher
Informa UK Limited
Online
2014-02-28
DOI
10.1586/14737140.2014.883922
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer
- (2017) M. A. Danso et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant therapy for stage II-III breast cancer with weekly nab-paclitaxel, every-three-week carboplatin, and targeted agents: Interim dose delivery and toxicity data.
- (2017) T. Rizack et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I study of neoadjuvant chemotherapy with nanoparticle albumin-bound paclitaxel, doxorubicin, and cyclophosphamide (NAC) in patients with stages II-III HER2-negative breast cancer.
- (2017) H. T. Khong et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial combining nab-paclitaxel (NP), gemcitabine (G), and bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): NCCTG N0735.
- (2017) D. W. Northfelt et al. JOURNAL OF CLINICAL ONCOLOGY
- Abstract P1-12-07: A Retrospective Analysis ofnab-Paclitaxel as First-Line Therapy for Metastatic Breast Cancer Patients With Poor Prognostic Factors
- (2014) J O'Shaughnessy et al. CANCER RESEARCH
- Randomized Phase II Trial of Weekly vs. Every 2 Weeks vs. Every 3 Weeks Nanoparticle Albumin-Bound Paclitaxel With Bevacizumab as First-Line Chemotherapy for Metastatic Breast Cancer
- (2013) Andrew D. Seidman et al. Clinical Breast Cancer
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2012) F. Cardoso et al. ANNALS OF ONCOLOGY
- 1st International consensus guidelines for advanced breast cancer (ABC 1)
- (2012) F. Cardoso et al. BREAST
- Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen
- (2012) Denise A. Yardley et al. BREAST CANCER RESEARCH AND TREATMENT
- Weeklynab-Paclitaxel in Metastatic Breast Cancer Summary and Results of an Expert Panel Discussion
- (2012) Christian Jackisch et al. Breast Care
- Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival
- (2012) William J. Gradishar et al. Clinical Breast Cancer
- Optimizing taxane use in MBC in the emerging era of targeted chemotherapy
- (2012) G. von Minckwitz et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Weeklynab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial
- (2012) Mark A. Socinski et al. JOURNAL OF CLINICAL ONCOLOGY
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
- (2012) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657
- (2012) Laura J. Esserman et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: A clinical review
- (2011) J. Chirgwin et al. BREAST
- Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib
- (2011) Virginia G. Kaklamani et al. BREAST CANCER RESEARCH AND TREATMENT
- Factors associated with mortality after breast cancer metastasis
- (2011) Su Yon Jung et al. CANCER CAUSES & CONTROL
- A Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel With or Without Trastuzumab in Metastatic Breast Cancer
- (2011) Barry Mirtsching et al. Clinical Breast Cancer
- Phase II Study of Neoadjuvant Weekly nab-Paclitaxel and Carboplatin, With Bevacizumab and Trastuzumab, As Treatment For Women With Locally Advanced HER2+ Breast Cancer
- (2011) Denise A. Yardley et al. Clinical Breast Cancer
- Phase II Multicenter Trial of Albumin-Bound Paclitaxel and Capecitabine in First-Line Treatment of Patients With Metastatic Breast Cancer
- (2011) Lee S. Schwartzberg et al. Clinical Breast Cancer
- Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
- (2010) Christopher Lobo et al. BREAST CANCER RESEARCH AND TREATMENT
- A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer
- (2010) Denise Yardley et al. BREAST CANCER RESEARCH AND TREATMENT
- Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study
- (2010) Nicholas Robert et al. BREAST CANCER RESEARCH AND TREATMENT
- A Phase II Trial of Dose-Dense Neoadjuvant Gemcitabine, Epirubicin, and Albumin-Bound Paclitaxel With Pegfilgrastim in the Treatment of Patients With Locally Advanced Breast Cancer
- (2010) Denise A. Yardley et al. Clinical Breast Cancer
- A Phase II Neoadjuvant Trial of Sequential Nanoparticle Albumin-Bound Paclitaxel Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide in Locally Advanced Breast Cancer
- (2010) André Robidoux et al. Clinical Breast Cancer
- Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel With Carboplatin and Trastuzumab as First-line Therapy for Women With HER2-Overexpressing Metastatic Breast Cancer
- (2010) Alison K. Conlin et al. Clinical Breast Cancer
- Rechallenging with anthracyclines and taxanes in metastatic breast cancer
- (2010) Carlo Palmieri et al. Nature Reviews Clinical Oncology
- Significantly Longer Progression-Free Survival Withnab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer
- (2009) William J. Gradishar et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane(R)) in combination with gemcitabine in patients with metastatic breast cancer (N0531)
- (2008) V. Roy et al. ANNALS OF ONCOLOGY
- A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer
- (2008) G. Fountzilas et al. BREAST CANCER RESEARCH AND TREATMENT
- Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and nab-Paclitaxel
- (2008) E. R. Gardner et al. CLINICAL CANCER RESEARCH
- Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840
- (2008) Andrew D. Seidman et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started